MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation at the AACR Annual Meeting from April 10-15, 2021, showcasing three innovative antibody-based therapeutic technologies. The highlighted therapeutic candidates include MGC018, which showed potent antitumor activity in mouse models, currently under Phase 1 trials for advanced solid tumors, margetuximab, designed to enhance immune responses, and IMGC936, directed against ADAM9-expressing tumors. The presentations signal MacroGenics' commitment to advancing its oncology pipeline.

Positive

• MGC018 demonstrated potent antitumor activity in preclinical models, indicating potential effectiveness against solid tumors.
• margetuximab enhances immune checkpoint blockade responses, potentially improving treatment outcomes.
• IMGC936 shows activity in various solid tumor types, expanding the therapeutic options in oncology.

Negative

• No specific financial metrics or clinical trial data were reported, which may raise concerns about transparency and investor confidence.

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.

“This year’s AACR presentations highlight three antibody-based technologies upon which multiple molecules are being developed at MacroGenics,” said Ezio Bonvini, M.D., Senior Vice President and Chief Scientific Officer of MacroGenics. “We are presenting pre-clinical data on MGC018, our clinical-stage, investigational antibody-drug conjugate (ADC) targeting B7-H3. At clinically relevant dose levels, MGC018 demonstrated potent antitumor activity in vivo in mouse patient-derived xenograft (PDX) models of squamous cell carcinoma of the head and neck (SCCHN). MGC018 is currently being investigated in a Phase 1 dose expansion study in advanced solid tumor cancers, including metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).”

“A second poster demonstrates that margetuximab, our Fc-engineered anti-HER2 mAb developed using our Fc Optimization platform, can upregulate checkpoint molecules on Natural Killer (NK) cells, CD8 T cells and tumor cells, potentially sensitizing them to immune checkpoint blockade. Consistent with this observation, PD-1 and LAG-3 blockade by tebotelimab, our investigational bispecific PD-1 × LAG-3 DART® molecule, enhances margetuximab-mediated NK cell cytolytic activity in vitro,” added Dr. Bonvini. “Finally, our third poster highlights pre-clinical data on IMGC936, an investigational ADAM9-directed ADC being developed in collaboration with ImmunoGen Inc. ADAM9 is highly expressed in a large number of solid tumors and our presentation shows that IMGC936 has activity against multiple solid tumor types in in vivo mouse PDX models. IMGC936 is currently being studied in a Phase 1 clinical trial evaluating safety and pharmacokinetics in cancer patients. Together, these results illustrate the drug development potential of all three technologies MacroGenics is deploying to identify and advance promising anti-cancer drug candidates.”

Presentation details are as follows:

April 10, 2021, 8:30 AM - 11:59 PM
1555 - Enhanced HER2-dependent immune activation by margetuximab, an investigational Fc-engineered anti-HER2 mAb, supports combination with checkpoint blockade
Session PO.IM02.02 - Combination Immunotherapies

April 10, 2021, 8:30 AM - 11:59 PM
950 - Targeting B7-H3 in squamous cell carcinoma of the head and neck: Preclinical proof-of-concept with the investigational anti-B7-H3 antibody-drug conjugate, MGC018
Session PO.ET07.01 - Biological Therapeutic Agents

April 10, 2021, 8:30 AM - 11:59 PM
1841 - IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models
Session PO.IM02.10 - Therapeutic Antibodies, Including Engineered Antibodies

Posters of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA’s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

###

FAQ

What were the highlights of MacroGenics' presentations at the AACR Annual Meeting 2021?

MacroGenics presented data on MGC018, margetuximab, and IMGC936, showcasing their therapeutic potential in oncology.

What is MGC018's current status in clinical trials?

MGC018 is currently being investigated in a Phase 1 dose expansion study for advanced solid tumors.

How does margetuximab work in cancer treatment?

Margetuximab is designed to enhance immune responses by upregulating checkpoint molecules.

What is the significance of IMGC936 in cancer therapy?

IMGC936 targets ADAM9, which is highly expressed in various solid tumors, showing promising preclinical results.